Taking statins can slightly raise your chance of getting type 2 diabetes, especially if you’re already at risk.
Scientific Claim
HMG-CoA reductase inhibition with statins modestly increases the risk of developing type 2 diabetes, particularly in individuals with pre-existing insulin resistance.
Original Statement
“There's also a small increase in diabetes risk. As I mentioned earlier, the absolute risk is quite modest, but it is real, particularly at higher doses and in people with existing insulin resistance.”
Context Details
Domain
pharmacology
Population
human
Subject
HMG-CoA reductase inhibition via statins
Action
increases
Target
risk of developing type 2 diabetes in insulin-resistant individuals
Intervention Details
Evidence from Studies
Supporting (2)
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials
This study found that statins, which lower cholesterol, also slightly raise blood sugar and weight, making it a bit more likely for people to develop type 2 diabetes — especially if they already have insulin problems. So yes, the study backs up the claim.
This study shows that statins, the cholesterol-lowering drugs, can make the liver produce more sugar and become less responsive to insulin — especially in people who are already insulin resistant — which helps explain why they might raise the risk of getting type 2 diabetes.
Contradicting (2)
This study gave kidney transplant patients with insulin resistance a common statin called pravastatin and found it didn't make their blood sugar worse — even though they were at high risk for diabetes. This goes against the idea that all statins increase diabetes risk.
This study gave people with early kidney disease a common cholesterol drug called pravastatin and found it didn’t make their blood sugar worse or increase diabetes risk — which goes against the idea that all statins raise diabetes risk.